Skip to content
Ad
Ad
Value Science Weekly — health economics and market access, in your inbox
→
Trending
HTA
Health AI
Drug Pricing
Oncology
Search Syenza News
Search
Partner with us
Newsletter
Home
Topics
HTA
HTA Policies
Cost-Effectiveness Analysis
Health Economic Evaluations
Health Policy
Healthcare Access
Health Equity & Access
Reimbursement Policy
Value-Based Healthcare
Real-World Evidence
Clinical Trials
Oncology & Cancer Research
AI & Machine Learning
Drug Safety
All topics →
Regions
Europe
North America
Sub-Saharan Africa
Middle East & North Africa
Asia
Latin America
Global
Events
Upcoming Events
Event Coverage
About
Visit Syenza
Home
/
Tezepelumab
Category
Tezepelumab
1 article in this topic.
Ad
Ad
Articles in this category
4/25/2023
Tezepelumab as an Add-on Maintenance Treatment for Severe Asthma: Recommendations and Clinical/Economic Impact.
Tezepelumab as an add-on maintenance treatment is recommended as an option for severe asthma in people 12 years and over, when treatment with high-dose inhaled corticosteroids plus another maintenance treatment has failed. It is recommended only if people: Have had 3 or more exacerbations in the previous year, or Are having maintenance oral corticosteroids. Tezepelumab should be discontinued if the rate of severe asthma exacerbations, or the maintenance oral corticosteroid dose, have not been reduced by at least 50% at […]
Read Article →
Related topics
Diseases
1
Europe
1
Middle East And North Africa
1
Severe Asthma
1
Sub Saharan Africa
1